NEWS 2020.10.14 Rebirthel concluded the research collaboration agreement with Fujita Health University. – Joint development of the therapy for the novel coronavirus infection using universal killer T cells –
Rebirthel concluded an agreement to collaborate with Fujita Health University to develop a new therapy for novel coronavirus infection and entered into the contract on October 14th, 2020. Killer T cells which are regenerated from iPS cells will be used. For details, please refer to the attached press release.